The objective of this study was to assess the real-world comparative effectiveness of continuing on allopurinol versus switching to febuxostat.

Methods: In a retrospective claims data study of enrollees in health plans affiliated with Optum, we evaluated patients from February 1, 2009, to May 31, 2012, with a gout diagnosis, a pharmacy claim for allopurinol or febuxostat, and at least 1 serum uric acid (SUA) result available during the follow-up period. Univariate and multivariable-adjusted analyses (controlling for patient demographics and clinical factors) assessed the likelihood of SUA lowering and achievement of target SUA of less than 6.0 mg/dL or less than 5.0 mg/dL in allopurinol continuers versus febuxostat switchers.

Results: The final study population included 748 subjects who switched to febuxostat from allopurinol and 4795 continuing users of allopurinol. The most common doses of allopurinol were 300 mg/d or less in 95% of allopurinol continuers and 93% of febuxostat switchers (prior to switching); the most common dose of febuxostat was 40 mg/d, in 77% of febuxostat switchers (after switching). Compared with allopurinol continuers, febuxostat switchers had greater (1) mean preindex SUA, 8.0 mg/dL versus 6.6 mg/dL (P < 0.001); (2) likelihood of postindex SUA of less than 6.0 mg/dL, 62.2% versus 58.7% (P = 0.072); (3) likelihood of postindex SUA of less than 5.0 mg/dL, 38.9% versus 29.6% (P < 0.001); and (4) decrease in SUA, 1.8 (SD, 2.2)mg/dL versus 0.4 (SD, 1.7)mg/dL (P < 0.001). In multivariable-adjusted analyses, compared with allopurinol continuers, febuxostat switchers had significantly higher likelihood of achieving SUA of less than 6.0 mg/dL (40% higher) and SUA of less than 5.0 mg/dL (83% higher).

Conclusions: In this “real-world” setting, many patients with gout not surprisingly were not treated with maximum permitted doses of allopurinol. Patients switched to febuxostat were more likely to achieve target SUA levels than those who continued on generally stable doses of allopurinol.

Key Words: comparative effectiveness, gout, medication switching, serum urate, urate-lowering therapy

A Real-World Study of Switching From Allopurinol to Febuxostat in a Health Plan Database

Aylin Altan, PhD,* Aki Shiozawa, MPH, MBA,† Tim Bancroft, MS, PhD,* and Jasvinder A. Singh, MD, MBBS, MPH‡

From the *Optum, Eden Prairie, MN; †Takeda Pharmaceuticals International, Inc, Deerfield, IL; and ‡Birmingham VA Medical Center; and Department of Medicine, School of Medicine, and Division of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, AL; and Department of Orthopedic Surgery, Mayo Clinic College of Medicine, Rochester, MN.

Author Contributions: A.A. participated actively in the statistical plan, data analysis, and drafting and review of the manuscript. J.A.S. participated actively in creating the concept and study design, review of data analysis, drafting, and review of the manuscript. T.B. had an active role in the data analysis and review of the manuscript. A.S. actively contributed to the study design, statistical plan, and review of the manuscript. All authors have read and approved the final manuscript.

This study was supported by Takeda Pharmaceuticals International, Inc. EPI-Q, Inc, provided medical writing assistance and editorial services for this manuscript and was compensated by Takeda Pharmaceuticals International, Inc. OptumInsight was hired by Takeda Pharmaceuticals International, Inc, to conduct analyses for this study.

Competing interests: A.S., as an employee of Takeda Pharmaceuticals International, was involved in the study design, review and interpretation of study results, and editing the final version of the submitted manuscript. A.A. and T.B. are employees of OptumInsight and were hired by Takeda Pharmaceuticals, Inc, to conduct the study analyses. J.A.S. has received research grants from Takeda and Savient and consultant fees from Savient, Takeda, Regeneron, and Allergan. J.A.S. is a member of the executive of OMERACT, an organization that develops outcome measures in rheumatology and receives arms-length funding from 36 companies; a member of the American College of Rheumatology’s Guidelines Subcommittee of the Quality of Care Committee; and a member of the Veterans Affairs Rheumatology Field Advisory Committee.

The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the US Government.

Correspondence: Jasvinder A. Singh, MD, MBBS, MPH, University of Alabama, Faculty Office Tower 805B, 510 20th St S, Birmingham, AL 35294. E-mail: Jasvinder.md@gmail.com.

Supplemental digital content is available for this article. Direct URL citation appears in the printed text and is provided in the HTML and PDF versions of this article on the journal’s Web site (www.jcronline.com).

Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially.

ISSN: 1076-1608
DOI: 10.1097/RHU.0000000000000322

Gout is the most common inflammatory arthritis condition in men older than 40 years and is increasingly prevalent among postmenopausal women. In addition, the prevalence of gout more than doubled between the 1960s and the 1990s. The National Health and Nutrition Examination Survey data showed that 8.3 million Americans have gout (3.9%) and 43.3 million (21.0%) have hyperuricemia, a major risk factor for gout. Hyperuricemia, defined as a serum uric acid (SUA) level greater than 6.8 mg/dL, is a key feature of gout.

Successful treatment of gout requires effective reduction of SUA with urate-lowering therapy (ULT). The most common pharmacologic approach to ULT is the use of xanthine oxidase inhibitors (XOIs), which reduce uric acid production. Allopurinol has been the principal XOI available for several decades, and febuxostat, a novel nonpurine analog XOI approved in the United States in 2009, has been shown to be noninferior in efficacy to allopurinol. Compared with allopurinol, febuxostat may require fewer dose adjustments in patients with mild to moderate renal dysfunction.

The European League Against Rheumatism and the British Society for Rheumatology gout treatment guidelines (which predate the US approval of febuxostat) recommend XOIs as the appropriate first-line treatment. The American College of Rheumatology guidelines recommend the use of allopurinol or febuxostat as the initial pharmacologic ULT. Both the American College of Rheumatology and the European League Against Rheumatism recommend that SUA levels be maintained at less than 6.0 mg/dL. Suboptimal treatment of gout and continued high SUA lead to recurrent attacks, tophaceous deposits, and joint damage.

In practice, allopurinol has been the first-line treatment, and when it fails or is associated with adverse effects, febuxostat is the second ULT option considered by most providers. To...
our knowledge, studies comparing the effectiveness (SUA change and SUA goal attainment) of continuing allopurinol versus switching therapy to febuxostat in the real-world setting have not been done. This was the primary objective of our study. Secondary objectives were to describe patient characteristics associated with changes in SUA and target SUA achievement in patients who switch from allopurinol to febuxostat.

METHODS
This retrospective claims data study used medical and pharmacy claims, enrollment information, and laboratory results for commercial and Medicare Advantage (with part D) enrollees in health plans affiliated with Optum (a diversified health management company) to assess the effectiveness of treatment with allopurinol versus febuxostat. This study was conducted using deidentified data from the Optum Research Database (ORD) accessed using methods compliant with the provisions of the Health Insurance Portability and Accountability Act of 1996. Because this study did not involve the collection, use, or transmittal of individually identifiable data, institutional review board review or approval was not required.

Data Source
The ORD contains encounter data from all health care sites (inpatient, hospital, outpatient, emergency room, physician’s office, surgery center, etc) for all types of provided services, including specialty, preventive, and office-based care. Claims for pharmacy services in the ORD included drug name, dosage form, drug strength, fill date, days of supply, financial information, and deidentified patient and prescriber codes. In addition, a proportion of outpatient laboratory test results are available to be linked to health care utilization and pharmacy claims data. During the identification period used for this project, the database included more than 56 million commercial

![Diagram](image-url)
and Medicare enrollees with both medical and pharmacy insurance coverage. The ORD database has been used for multiple gout studies previously.

**Study Population**

To be eligible for study inclusion, enrollees met the following criteria during the identification period, February 1, 2009, to May 31, 2012: (1) had at least 1 medical claim with the International Classification of Diseases, Ninth Revision, Common Modification diagnosis code for gout (274.xx); (2) had a least 1 pharmacy claim for allopurinol or febuxostat; (3) were continuously enrolled for at least 6 months prior to the index date and at least 3 months following the index date; and (4) had at least 1 SUA laboratory test (CPT codes 84550, 84560) result available at 14 days or more after the index date. This corresponds to the earliest post-ULT SUA test codes 84550, 84560) result available at 14 days or more after the index date. The date of first prescription fill, within the study period, for febuxostat or allopurinol was defined as the subject’s index date. If a subject had prescription fills for both medications, the first fill for febuxostat was defined as the index date, and the subject was identified as a “febuxostat switcher” (from allopurinol to febuxostat). Subjects were excluded if they were younger than 18 years as of the year of the index date, had evidence of cancer by International Classification of Diseases, Ninth Revision, Common Modification codes during the study period, or received an index dose of XOIs outside the recommended dosage range (<100 mg/d or >1500 mg/d for allopurinol and any dose not equaling 40 or 80 mg/d for febuxostat, doses approved for use by the US Food and Drug Administration [FDA]). Baseline data were obtained during the 6-month period prior to the index date. Subjects were followed up until September 30, 2012, until the subject was no longer enrolled in the health plan or death, whichever came first.

**Study Cohorts**

The study sample includes all available subjects in the database who met the study inclusion and exclusion criteria during the defined time period. Subjects (all of whom had prescriptions for allopurinol filled prior to the index date) were assigned to 1 of 2 study cohorts based on their index medication fill (febuxostat vs allopurinol): (1) continued allopurinol (allopurinol continuers) or (2) switched from allopurinol to febuxostat (febuxostat switchers).

**Study Outcome Measures**

Outcomes were assessed during a variable follow-up period of a minimum of 3 months through a maximum of 3½ years following the index date. The main outcome measure was change from preindex to postindex mean SUA level. The SUA test values were captured during the preindex (average and final values) and postindex periods. Effectiveness of allopurinol or febuxostat was assessed by their ability to lower SUA, which was examined as a binary indicator of achieving the target SUA of less than 6.0 mg/dL and less than 5.0 mg/dL using logistic regression controlling for demographics, comorbid conditions, baseline gout flare rates, and anti-inflammatory prophylaxis. Among febuxostat switchers, multivariable-adjusted logistic regression analyses were used to determine whether certain patient characteristics (age groups, sex, presence of renal failure) were associated with a greater degree of success in lowering or achieving the target SUA levels with febuxostat treatment. All analyses were performed using SAS version 9.2 (SAS Institute Inc., Cary, NC, USA) and Stata version 12 (StataCorp., College Station, TX). The 2-tailed level of significance was set at the 0.05 level.

**Statistical Analysis**

The primary objective was to compare change in SUA, proportion of subjects achieving SUA target, and mean postindex SUA. Subject demographics (age, sex, and region) and baseline clinical characteristics (utilization and comorbid conditions assessed by Quan-Charlson comorbidity score<sup>18</sup>) were compared using χ² or t test as appropriate. Comparisons of categorical outcomes of interest (postindex SUA goal <6.0 and <5.0 mg/dL) were conducted using McNemar test (bivariate) and logistic regression (multivariable adjusted). Continuous measures (preindex and postindex prescription SUA and creatinine, time to SUA) were examined using a paired Student t test. Multivariable-adjusted analysis was conducted for binary indicators of achieving the target SUA of less than 6.0 mg/dL and less than 5.0 mg/dL using logistic regression controlling for demographics, comorbid conditions, baseline gout flare rates, and anti-inflammatory prophylaxis. Among febuxostat switchers, multivariable-adjusted logistic regression analyses were used to determine whether certain patient characteristics (age groups, sex, presence of renal failure) were associated with a greater degree of success in lowering or achieving the target SUA levels with febuxostat treatment. All analyses were performed using SAS version 9.2 (SAS Institute Inc., Cary, NC, USA) and Stata version 12 (StataCorp., College Station, TX). The 2-tailed level of significance was set at the 0.05 level.

**RESULTS**

**Study Cohort Selection and Baseline Characteristics**

Figure 1 outlines the patient attrition and assembly of the cohorts. The final population meeting inclusion/exclusion criteria was 5543. Of these, 748 switched to febuxostat from allopurinol, and 4795 were continuing users of allopurinol. The average age of febuxostat switchers and allopurinol continuers was 56.7 and 55.2 years, respectively (Table 1; P = 0.003). The majority of subjects in both groups were male (83.2% of febuxostat switchers, 91.5% of allopurinol continuers; P < 0.001), were commercially insured (77.7% vs 93.7%; P < 0.001) and lived in the South (74.3% vs 68.2%; P < 0.001) in part because of the distribution of the affiliated health plan’s enrollment. In allopurinol continuers, the most common dose was 300 mg/d (64%) followed

| TABLE 1. Baseline Characteristics for Febuxostat Switchers and Allopurinol Continuers |
|---------------------------------|---------------------------------|-----------------|
| Febuxostat Switchers (n = 748)  | Allopurinol Continuers (n = 4795) | P                |
| Age, mean (SD), y               | 56.7 (12.7)                      | 55.23 (10.4)     | 0.003 |
| Age, n (%)                      | 18–44 y                          | 138 (18.5)       | 760 (15.9) | 0.073 |
|                                | 45–64 y                          | 396 (52.9)       | 3216 (67.1) | <0.001 |
|                                | 65–74 y                          | 145 (19.4)       | 634 (13.2)  | <0.001 |
|                                | ≥75 y                            | 69 (9.2)         | 185 (3.9)   | <0.001 |
| Sex, n (%)                      | Male                             | 622 (83.2)       | 4385 (91.5) | <0.001 |
|                                | Insurance type, n (%)            |                  |              |       |
|                                | Commercial                       | 581 (77.7)       | 4493 (93.7) | <0.001 |
|                                | Medicare Advantage               | 167 (22.3)       | 302 (6.3)   | <0.001 |
|                                | Geographical region, n (%)       |                  |              |       |
|                                | Northeast                        | 35 (5.1)         | 397 (8.3)   | 0.002 |
|                                | Midwest                          | 60 (8.0)         | 426 (8.9)   | 0.438 |
|                                | South                            | 556 (74.3)       | 3270 (68.2) | <0.001 |
|                                | West                             | 94 (12.6)        | 702 (14.6)  | 0.133 |

© 2015 Wolters Kluwer Health, Inc. All rights reserved.
by less than 300 mg/d (31%) and rarely more than 300 mg/d (5%). Similarly, the most common allopurinol doses were 300 mg/d or less in 93% in febuxostat switchers, prior to switching from allopurinol to febuxostat. Febuxostat switchers mostly received 40 mg/d (77%) and less commonly received febuxostat dose of 80 mg/d (23%). Dose increase occurred in 21% of febuxostat switchers versus 15% allopurinol continuers.

SUA Outcomes: Febuxostat Switchers Compared With Allopurinol Continuers

Compared with allopurinol continuers, febuxostat switchers had statistically significantly higher mean preindex SUA (8.0 vs 6.6 mg/dL, \( P < 0.001 \); Table 2). Febuxostat switchers had a greater decrease in SUA (1.8 [SD, 2.2] mg/dL decrease) following the initiation of febuxostat, compared with allopurinol continuers (0.4 [SD, 1.7] mg/dL decrease; \( P < 0.001 \)). In the postindex period, 62.2% of febuxostat switchers versus 58.7% of allopurinol continuers achieved an SUA of less than 6.0 mg/dL (\( P = 0.072 \); Fig. 2). Respective proportions were 38.9% versus 29.6% for achieving SUA of less than 5.0 mg/dL (\( P < 0.001 \); Fig. 2).

In multivariable-adjusted logistic regression models, patients who switched from allopurinol to febuxostat had a 40% higher likelihood of achieving SUA goal of less than 6.0 mg/dL and an 82% higher likelihood of attaining goal of less than 5.0 mg/dL (Table 3). The adjusted probability of goal attainment of less than 6.0 mg/dL was 65.6% among febuxostat switchers compared with 58.1% for allopurinol continuers (41.9% vs 23.9% adjusted probability of goal attainment <5.0 mg/dL).

**DISCUSSION**

Our study population is comparable to the US population. Sixteen percent of enrollees reside in the Western census region, by less than 300 mg/d (31%) and rarely more than 300 mg/d (5%). Similarly, the most common allopurinol doses were 300 mg/d or less in 93% in febuxostat switchers, prior to switching from allopurinol to febuxostat. Febuxostat switchers mostly received 40 mg/d (77%) and less commonly received febuxostat dose of 80 mg/d (23%). Dose increase occurred in 21% of febuxostat switchers versus 15% allopurinol continuers.

**SUA Outcomes Among Febuxostat Switchers**

Febuxostat effectiveness was assessed among febuxostat switchers only by sex, age, presence of renal failure, and Quan-Charlson index (Supplementary Table S1, available at http://links.lww.com/RHU/A56). Females were more likely than males to achieve SUA of less than 5.0 mg/dL (\( P = 0.045 \)) and achieved it an average of more than 3 months sooner than did men (\( P = 0.003 \); Supplementary Table S1). Among febuxostat switchers, compared with younger subjects, older subjects were significantly more likely to achieve SUA of less than 5.0 mg/dL (\( P < 0.001 \)) or 6.0 mg/dL (\( P = 0.006 \)) and achieved both goals sooner (\( P < 0.001 \) for both). For example, subjects 75 years or older achieved SUA of less than 5.0 mg/dL an average of approximately 8 months earlier than did subjects younger than 50 years. These older subjects achieved SUA of less than 6.0 mg/dL an average of approximately 6 months earlier than did subjects younger than 50 years. Subjects with renal failure had a greater percent SUA reduction (28.5% vs 18.4%, \( P = 0.034 \)) and absolute SUA reduction (2.9 vs 1.7 mg/dL, \( P = 0.013 \)) from pre- to post-SUA. No significant differences in SUA outcomes were noted by Quan-Charlson comorbidity index (Supplementary Table S1). Multivariable-adjusted analyses after controlling for patient characteristics showed that age had a borderline statistically significant trend for SUA goals of less than 6.0 and less than 5.0 mg/dL. A higher preindex SUA was associated with statistically significantly lower likelihood of achieving the target SUA (Table 4).

**TABLE 2. Unadjusted Pre-and Post-Index SUA Values in Febuxostat Switchers and Allopurinol Continuers**

|                | Febuxostat Switchers | Allopurinol Continuers |
|----------------|----------------------|------------------------|
| Preindex SUA\(^a\) | 7.96 (1.91)          | 6.58 (1.80)            | <0.001     |
| Postindex SUA\(^b\) | 6.22 (1.95)          | 6.21 (1.56)            | 0.902      |
| Decrease in SUA\(^c\) | -1.76 (2.16)         | -0.36 (1.67)           | <0.001     |

\(^a\)Average of all preindex SUA measurements.
\(^b\)Average of all postindex SUA measurements.
\(^c\)Among those with at least 1 baseline measurement and 1 follow-up measurement, decrease was defined as the difference between the mean preindex SUA measurement and the mean postindex SUA.

**FIGURE 2.** Percentages of patients achieving SUA goal.

SUA = serum uric acid

**FIGURE 2.** Percentages of patients achieving SUA goal.
compared with 24% for the US population overall; 36% of members reside in the Southern regions, 20% in the Midwest, and 27% in the Northeastern region (compared with 37%, 21%, and 18% in the US population overall).19 In addition, the commercial and Medicare Advantage Health plan enrollees in the ORD health plans used in this study are similar to US insured and Medicare populations, respectively.20 The ORD has been used in numerous research studies in patients with gout evaluating gout treatment patterns, costs, and the occurrence of flares.15–17

In this retrospective study that included patients similar to the general US population, we made several important observations that merit further discussion.

We found that patients who switched from allopurinol to febuxostat achieved the target SUA of less than 6.0 mg/dL and less than 5.0 mg/dL more often than did the allopurinol continuers, despite having a higher preindex SUA, 8.0 versus 6.6 mg/dL, respectively. This observation persisted in multivariable-adjusted analyses after accounting for demographics, comorbidity, annual costs, preindex SUA, and serum creatinine, among other factors. Patients who switched from allopurinol to febuxostat had a 1.40 and 1.83 times higher likelihood of achieving SUA goal of less than 6.0 mg/dL and less than 5.0 mg/dL, respectively. Febuxostat switchers appeared to have more severe disease (higher SUA at baseline, more gout flares), higher medical comorbidity, and higher disease burden (health care resource utilization and cost) at baseline. The proportion of patients receiving allopurinol of 300 mg/d or less was similar in allopurinol continuers versus febuxostat switchers, 95% versus 93%. These results are supported by a large population-based cohort study that found patients initiated on febuxostat had more comorbidities and greater

**TABLE 3. Multivariable-Adjusted Logistic Regression Analysis of SUA Goal Attainment Less Than 6 mg/dL and Less Than 5 mg/dL in Febuxostat Switchers Versus Allopurinol Continuers**

| Independent Variables | Dependent Variable SUA Goal Attainment <6 mg/dL | Odds Ratio Lower 95% CI Upper 95% CI P | Dependent Variable SUA Goal Attainment <5 mg/dL | Odds Ratio Lower 95% CI Upper 95% CI P |
|-----------------------|-----------------------------------------------|----------------------------------------|-----------------------------------------------|----------------------------------------|
| Febuxostat switchers (vs allopurinol continuers) | 1.403 1.166 1.687 <0.001 | 1.825 1.510 2.205 <0.001 |
| Age<sup>a</sup> | <0.001 | <0.001 |
| 18–44 y | 0.637 0.544 0.745 <0.001 | 0.669 0.556 0.805 <0.001 |
| 65–74 y | 1.364 1.130 1.646 0.001 | 1.300 1.079 1.565 0.006 |
| ≥75 y | 1.330 0.939 1.884 0.108 | 1.605 1.143 2.254 0.006 |
| Male<sup>b</sup> | 0.829 0.676 1.018 0.073 | 0.675 0.552 0.826 <0.001 |
| Baseline uricosuric/incidental uricosuric medication use | 1.005 0.871 1.160 0.942 | 1.049 0.903 1.219 0.529 |
| Baseline comorbidities | | |
| Coronary artery disease | 1.116 0.909 1.369 0.295 | 1.176 0.957 1.445 0.124 |
| Heart failure | 0.699 0.501 0.975 0.035 | 0.743 0.521 1.059 0.100 |
| Hypertension | 1.046 0.917 1.194 0.502 | 0.988 0.857 1.139 0.867 |
| Hyperlipidemia | 1.112 0.979 1.265 0.103 | 1.119 0.975 1.285 0.110 |
| Kidney failure | 1.086 0.679 1.738 0.730 | 1.121 0.690 1.822 0.644 |
| Obesity | 0.948 0.755 1.190 0.643 | 1.086 0.853 1.382 0.505 |
| Baseline gout flare | 0.938 0.831 1.058 0.297 | 0.869 0.763 0.990 0.034 |
| Baseline per member per month health care costs (in $1000) | 1.007 0.982 1.033 0.585 | 1.021 0.996 1.047 0.108 |
| SUA quartiles<sup>c</sup> | <0.001 | <0.001 |
| q2 (6.21–7.90) | 0.251 0.175 0.360 <0.001 | 0.226 0.169 0.302 <0.001 |
| q3 (7.91–9.40) | 0.129 0.090 0.184 <0.001 | 0.151 0.111 0.206 <0.001 |
| q4 (9.41+) | 0.094 0.065 0.136 <0.001 | 0.122 0.088 0.169 <0.001 |
| Missing | 0.207 0.150 0.286 <0.001 | 0.287 0.227 0.363 <0.001 |
| SCr quartiles<sup>d</sup> | 0.002 | 0.006 |
| q2 (1.03–1.24) | 0.980 0.762 1.262 0.878 | 0.960 0.748 1.232 0.748 |
| q3 (1.25–1.53) | 0.824 0.645 1.053 0.121 | 0.792 0.617 1.016 0.067 |
| q4 (≥1.54) | 0.724 0.557 0.940 0.016 | 0.810 0.620 1.060 0.125 |
| Missing | 0.694 0.560 0.861 <0.001 | 0.694 0.559 0.862 <0.001 |

Additional variables included in the model were insurance type, baseline comorbidities (angina, diabetes, dialysis, kidney stones, myocardial infarction, overweight, osteoarthritis, peripheral artery disease, stroke). Uricosuric medications were defined as probenecid and colchicine. Incidental uricosuric medications were defined as losartan, amlodipine, fenofibrate, niacin, or gemfibrozil.

<sup>a</sup>Reference group: 45 to 64 years of age.

<sup>b</sup>Reference group: females.

<sup>c</sup>Reference group: q1 (2.00–6.20).

<sup>d</sup>Reference group: q1 (0.58–1.02).

CI indicates confidence interval; q, quartiles; SCr, serum creatinine.
use of health care resources and gout-related drugs such as opioids, steroids, and anti-inflammatory drugs than did the allopurinol users. This potentially implies that a higher severity of gout is associated with initiation or change in the treatment to febuxostat. Another interpretation of these data is that in patients with gout with significant comorbidity burden, who fail to lower the SUA appropriately (or achieve SUA goal) with allopurinol, febuxostat may be an effective alternative. An important consideration is that despite the FDA approved dose of allopurinol up to 800 mg/d, only 5% of allopurinol continuers had a daily allopurinol dose of greater than 300 mg/d, and allopurinol dose was titrated up only in 15% cases during the study period. This contrasts with 23% of febuxostat switchers receiving the highest FDA-approved febuxostat dose of 80 mg/d and the overall up-titration in 21% of cases. It is common knowledge that less than 50% of patients treated with allopurinol with doses 300 mg/d or lower achieve a target serum urate of less than 6 mg/dL. Multivariable-adjusted analyses showed that in febuxostat switchers increased age had borderline association with the higher likelihood of achieving SUA goals of less than 6.0 and less than 5.0 mg/dL. A higher preindex SUA was associated with a lower likelihood of achieving the target SUA during follow-up. None of the other investigated factors were associated with successfully reaching SUA target. Lower adherence to ULT and a higher body mass index in younger patients with gout may be the reasons for the older febuxostat switchers to be more likely to reach the target SUA than the younger patients. This phenomenon has been demonstrated recently in other studies as well and suggests that the treatment of gout needs to be aggressive, especially in younger patients because they have less optimal outcomes with XOI treatment for urate lowering than do older patients.

Our study findings must be interpreted considering several limitations. Claims data are collected for the purpose of payment/reimbursement (not research), and therefore, it can have limitations. Claim data are collected for the purpose of payment/reimbursement (not research), and therefore, it can have limitations.

---

### TABLE 4. Multivariable-Adjusted Association of Clinical, Laboratory, and Health Coverage Variables With SUA Goal Attainment in Febuxostat Switchers

| Independent Variables | SUA Goal Attainment <6 mg/dL | SUA Goal Attainment <5 mg/dL |
|------------------------|-------------------------------|-------------------------------|
|                        | Odds Ratio 95% CI | Odds Ratio 95% CI |
| Age[^a^]               | 0.063 | 0.003 |
| 18–44 y                | 0.583 0.381 0.892 0.013 | 0.418 0.258 0.678 <0.001 |
| 65–74 y                | 0.770 0.463 1.280 0.314 | 0.859 0.517 1.427 0.557 |
| ≥75 y                  | 1.123 0.532 2.368 0.761 | 1.303 0.639 2.653 0.467 |
| Male[^b^]              | 0.830 0.513 1.343 0.448 | 0.986 0.623 1.559 0.952 |
| Baseline uricosuric/incidental medication use | 0.874 0.595 1.285 0.494 | 1.001 0.682 1.471 0.994 |

**Baseline comorbidities**

- Coronary artery disease: 0.676 0.400 1.142 0.143
- Heart failure: 0.644 0.317 1.306 0.223
- Hypertension: 1.201 0.810 1.781 0.363
- Hyperlipidemia: 1.322 0.936 1.867 0.113
- Kidney failure: 1.867 0.800 4.354 0.113
- Obesity: 0.713 0.406 1.253 0.237
- Baseline urate (per member per month health care costs): 0.997 0.797 1.040 0.879

**SUA quartiles[^c^]**

- q2 (6.21–7.90): 0.429 0.224 0.823 0.011
- q3 (7.91–9.40): 0.211 0.114 0.389 <0.001
- q4 (9.41): 0.249 0.128 0.485 <0.001
- Missing: 0.358 0.192 0.669 0.011

**SCR quartiles[^d^]**

- q2 (1.03–1.24): 0.834 0.465 1.493 0.541
- q3 (1.25–1.53): 0.708 0.390 1.286 0.257
- q4 (2.54): 0.558 0.291 1.073 0.080
- Missing: 0.631 0.353 1.127 0.120

[^a^]: Reference group: 45 to 64 years of age.
[^b^]: Reference group: females.
[^c^]: Reference group: q1 (2.00–6.20).
[^d^]: Reference group: q1 (0.58–1.02).

CI indicates confidence interval; q, quartiles; SCR, serum creatinine.
in terms of accuracy. The degree to which claims data can accurately capture medical history at the level of an individual is subject to errors in coding in the record and to codes included as a “rule-out” criterion rather than indicating the presence of actual disease. Pharmacy claims do not fully reflect actual patient dosing or compliance/adherence with a medication regimen. Socioeconomic factors and physician practice (subtherapeutic doses of allopurinol, poor adherence with quality care) could play a role in treated patients not achieving the target SUA goal. These data were not captured, a limitation of our study. This study does not control for adherence with ULT medications or the use of other medications such as diuretics, both of which can impact serum urate outcome; if they differed between the 2 groups, they might partially explain the differences in outcomes. However, the switch from allopurinol to febuxostat is usually done because of lack of efficacy or adverse effects associated with allopurinol and not based on use versus nonuse of diuretics. Both medications are administered once daily and have similarly low risk of adverse events, and therefore we do not anticipate major differences in adherence based on these factors. A study limitation is that adherence was not measured in our study. Therefore, if differences in adherence exist, they might partially explain febuxostat versus allopurinol difference. A numerically slightly higher dose titration for febuxostat switchers versus allopurinol continues (21% vs 15%) might have partially contributed to outcome differences. However, these comparative effectiveness results from this “real world” are still valid, because we are comparing effectiveness, which incorporates factors such as adherence, dose titration, and so on. However, the reader must interpret these findings being from an effectiveness study, not an efficacy study. The results of this analysis are primarily applicable to the interpretation of trends or patterns of XOI use in patients with gout who are similarly insured in the US population and may not be generalizable to other patient populations such as the noninsured or Medicaid-insured patients.

In conclusion, this study shows that in allopurinol-to-febuxostat switchers, almost two-thirds achieve SUA of less than 6.0 mg/dL, and a third achieve SUA of less than 5.0 mg/dL. These proportions were slightly higher than those achieved in patients who continued allopurinol. In addition, febuxostat switchers achieved the target SUA faster than did the allopurinol continuers. Further studies are needed to evaluate if this leads to any significant differences in quality of life or functional ability or gout flare frequency, outcomes directly relevant to patients, and if these findings are sustained over time. We also identified the factors associated with effectiveness of febuxostat in achieving the target SUA goal, in patients with gout who switched to febuxostat. These findings should help to identify high-risk gout patient populations who are likely to benefit the most with aggressive ULT with a frequent monitoring of their disease and SUA.

REFERENCES

1. Lawrence RC, Felson DT, Helmick CG, et al. National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 2008;58:26–35.

2. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007–2008. Arthritis Rheum. 2011;63:3136–3141.

3. Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353:2450–2461.

4. Bruce SP. Febuxostat: a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout. Ann Pharmacother. 2006;40:2187–2194.

5. Edwards NL. Febuxostat: a new treatment for hyperuricaemia in gout. Rheumatology (Oxford). 2009;48(suppl 2):i15–i19.

6. Zhang W, Doherty M, Bardin T, et al. EULAR Standing Committee for International Clinical Studies Including Therapeutics. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65:1312–1324.

7. Zhang W, Doherty M, Pascaul E, et al. EULAR Standing Committee for International Clinical Studies Including Therapeutics. EULAR evidence based recommendations for gout. Part I: diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65:1301–1311.

8. Jordan KM, Cameron JS, Snash M, et al. British Society for Rheumatology and British Health Professionals in Rheumatology Standards, Guidelines and Audit Working Group (SGAWG). British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford). 2007;46:1372–1374.

9. Khanna D, Fitzgerald JD, Khanna PP, et al. American College of Rheumatology. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012;64:1431–1446.

10. Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum. 2004;51:321–325.

11. Sarawate CA, Patel PA, Schumacher HR, et al. Serum urate levels and gout flares: analysis from managed care data. J Clin Rheumatol. 2006;12:61–65.

12. Perez-Ruiz F, Calabozo M, Pijoan JI, et al. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum. 2002;47:356–360.

13. Khanna D, Khanna PP, Fitzgerald JD, et al. American College of Rheumatology. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken). 2012;64:1447–1461.

14. Kim SC, Schmidt BM, Franklin JM, et al. Clinical and health care use characteristics of patients newly starting allopurinol, febuxostat, and colchicine for the treatment of gout. Arthritis Care Res (Hoboken). 2013;65:2008–2014.

15. Halpern R, Fuldeore MJ, Mody RR, et al. The effect of serum urate on gout flares and their associated costs: an administrative claims analysis. J Clin Rheumatol. 2009;15:3–7.

16. Halpern R, Mody RR, Fuldeore MJ, et al. Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis. Curr Med Res Opin. 2009;25:1711–1719.

17. Riedel AA, Nelson M, Joseph-Ridge N, et al. Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims. J Rheumatol. 2004;31:1575–1581.

18. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43:1130–1139.
19. US Department of Commerce, US Census Bureau. State Totals: Vintage 2013 Estimates of the Components of Resident Population Change for the United States, Regions, States, and Puerto Rico: April 1, 2010, to July 1, 2013. Available at: http://www.census.gov/popest/data/state/totals/2013/. Accessed April 6, 2014.

20. Pandya BJ, Riedel AA, Swindle JP, et al. Relationship between physician specialty and allopurinol prescribing patterns: a study of patients with gout in managed care settings. *Curr Med Res Opin*. 2011;27:737–744.

21. Singh JA, Hodges JS, Asch SM. Opportunities for improving medication use and monitoring in gout. *Ann Rheum Dis*. 2009;68:1265–70.

22. Zandman-Goddard G, Amital H, Shamrayevsky N, et al. Rates of adherence and persistence with allopurinol therapy among gout patients in Israel. *Rheumatology (Oxford)*. 2013;52:1126–1131.

23. Kumar S, Gupta R, Suppiah R. Gout in women: differences in risk factors in young and older women. *NZ Med J*. 2012;125:39–45.